- Home
- SENEA vs CGEM Comparison
SENEA vs CGEM Comparison
Compare SENEA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEA | CGEM |
|---|---|---|
| Founded | 1949 | 2016 |
| Country | United States | United States |
| Employees | 6895 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 908.7M | 904.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SENEA | CGEM |
|---|---|---|
| Price | $142.76 | $14.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $30.13 |
| AVG Volume (30 Days) | 80.9K | ★ 784.0K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.20 |
| P/E Ratio | $13.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $87.99 | $5.68 |
| 52 Week High | $167.52 | $16.74 |
Technical Indicators
Market Signals| Indicator | SENEA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 54.01 |
| Support Level | $138.19 | $11.92 |
| Resistance Level | $148.36 | $16.10 |
| Average True Range (ATR) | 5.56 | 0.98 |
| MACD | 0.40 | 0.15 |
| Stochastic Oscillator | 66.95 | 66.07 |
Price Performance
Historical ComparisonAbout SENEA Seneca Foods Corp.
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.